MCKESSON REVEALS INTENT TO CHANGE CFO
- Company Announcement: MCKESSON has announced a planned transition for its Chief Financial Officer (CFO).
- Transition Details: The announcement includes specifics about the timeline and process for the CFO transition.
Trade with 70% Backtested Accuracy
Analyst Views on MCK
About MCK
About the author
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
Stocks Decline as Oil Prices Surge Following Iran's Attack
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 50 shares of Cardinal Health (CAH) at approximately $214 each on Wednesday, raising its total holdings to 450 shares and increasing the portfolio weighting from 2.27% to 2.55%, reflecting confidence in the company.
- Market Reaction: Since the onset of the Middle East conflict, energy prices and stocks have shown an inverse relationship, with rising oil prices leading to stock sell-offs and concerns about inflation, as evidenced by the S&P 500's decline of over 0.5%.
- Financial Outlook: Cardinal Health generates nearly 100% of its revenue in the U.S., and management indicated that the recent commodity price spike will have an immaterial impact on its fiscal year 2026 earnings, showcasing its resilience and prompting investors to accumulate shares during market weakness.
- Industry Dynamics: Despite the healthcare sector's poor performance this month and the retirement of two CFOs raising concerns, Cencora's reaffirmation of its financial guidance has alleviated fears of an impending shortfall, indicating stability within the industry.
Three Stocks Likely to Announce Upcoming Stock Splits
Stock Splits Overview: Stock splits are actions taken by companies to make their shares more affordable for retail investors, typically occurring after periods of significant growth or innovation.
Investor Psychology: The intrinsic value of a company remains unchanged after a stock split, but investor psychology plays a crucial role in driving short-term performance, as lower-priced shares may attract more buyers.
Examples of Companies: Companies like Costco and Walmart have announced stock splits, with Costco's stock trading over $1,000 per share and Walmart's split planned for January 2024, reflecting strong share price growth.
Future Stock Splits: Analysts suggest that companies like KLA Corporation and Eli Lilly may consider stock splits in the future, driven by their strong growth stories and increasing share prices, which could benefit investors.
Stocks Decline Amid Middle East Conflict and Mixed Economic Data
- Escalating Middle East Conflict: The U.S. and Israel's bombing of Iran has pressured global stocks, with the S&P 500 dropping 2% last week, while oil prices surged to $90 per barrel, marking a 35% weekly gain, the largest since 1983, indicating potential economic repercussions.
- Mixed Economic Data: Although the ADP report indicated a rise of 63,000 private sector jobs in February, surpassing expectations, the subsequent nonfarm payroll report revealed an increase in the unemployment rate to 4.4%, highlighting emerging job losses due to AI and creating uncertainty about the economic outlook.
- Earnings Impact: Broadcom exceeded earnings expectations, resulting in a 3.4% stock increase, while Corning's shares fell nearly 7% following comments from Broadcom's CEO that dampened optimism about fiber-optic technology, reflecting market volatility in tech sectors.
- Investment Strategy Adjustments: Amid market fluctuations, the investment club increased its position in Cardinal Health and exited BlackRock entirely due to rising private credit concerns, demonstrating a proactive approach to navigating the current market landscape.
Three Dividend Growth Stocks Steadily Increasing Their Payouts
Market Volatility and Investment Strategy: With increasing market volatility, investors are considering a shift towards more defensive investment strategies, particularly focusing on dividend stocks that have a history of stable increases.
Broadcom's Performance: Broadcom Inc. is highlighted as a strong player in the AI and semiconductor sectors, with significant revenue growth and a consistent history of dividend increases, making it an attractive option for investors.
McKesson's Resilience: McKesson Corporation is noted for its stable dividend payments and growth potential, despite short-term challenges, supported by its diversified business model in healthcare.
Amphenol's Dividend Growth: Amphenol Corporation has demonstrated a strong track record of dividend increases, positioning itself as a reliable investment option, with expectations for continued earnings growth in the coming year.
McKesson Reports Strong Q3 Fiscal 2026 Results Driven by Specialty Growth
- Core Business Growth: McKesson achieved an 11% revenue growth and a 13% operating profit growth in Q3, primarily driven by broad momentum in oncology, multispecialty, and pharmaceutical distribution, showcasing the company's strong competitiveness in high-growth healthcare sectors.
- Specialty Drug Boost: Revenues from GLP-1 therapies rose 26% year-over-year to $14 billion, indicating the company's significant advantage in distributing high-cost, complex therapies, which enhances margins and market share.
- Acquisition-Driven Profitability: The oncology and multispecialty segment saw a 57% operating profit growth, supported by acquisitions like PRISM Vision and Florida Cancer Specialists, reinforcing McKesson's strategic position in high-margin service platforms.
- Medical-Surgical Segment Challenges: The Medical-Surgical segment reported only 1% revenue growth and a 10% decline in operating profit, reflecting its sensitivity to external factors, which may limit overall growth potential and impact consolidated performance.
Stocks Decline as Oil Prices Surge Following Iran's Attack
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
Jim Cramer's Trust Increases Stake in Cardinal Health
- Increased Stake: Jim Cramer's Charitable Trust purchased 50 shares of Cardinal Health (CAH) at approximately $214 each on Wednesday, raising its total holdings to 450 shares and increasing the portfolio weighting from 2.27% to 2.55%, reflecting confidence in the company.
- Market Reaction: Since the onset of the Middle East conflict, energy prices and stocks have shown an inverse relationship, with rising oil prices leading to stock sell-offs and concerns about inflation, as evidenced by the S&P 500's decline of over 0.5%.
- Financial Outlook: Cardinal Health generates nearly 100% of its revenue in the U.S., and management indicated that the recent commodity price spike will have an immaterial impact on its fiscal year 2026 earnings, showcasing its resilience and prompting investors to accumulate shares during market weakness.
- Industry Dynamics: Despite the healthcare sector's poor performance this month and the retirement of two CFOs raising concerns, Cencora's reaffirmation of its financial guidance has alleviated fears of an impending shortfall, indicating stability within the industry.
Three Stocks Likely to Announce Upcoming Stock Splits
Stock Splits Overview: Stock splits are actions taken by companies to make their shares more affordable for retail investors, typically occurring after periods of significant growth or innovation.
Investor Psychology: The intrinsic value of a company remains unchanged after a stock split, but investor psychology plays a crucial role in driving short-term performance, as lower-priced shares may attract more buyers.
Examples of Companies: Companies like Costco and Walmart have announced stock splits, with Costco's stock trading over $1,000 per share and Walmart's split planned for January 2024, reflecting strong share price growth.
Future Stock Splits: Analysts suggest that companies like KLA Corporation and Eli Lilly may consider stock splits in the future, driven by their strong growth stories and increasing share prices, which could benefit investors.
Stocks Decline Amid Middle East Conflict and Mixed Economic Data
- Escalating Middle East Conflict: The U.S. and Israel's bombing of Iran has pressured global stocks, with the S&P 500 dropping 2% last week, while oil prices surged to $90 per barrel, marking a 35% weekly gain, the largest since 1983, indicating potential economic repercussions.
- Mixed Economic Data: Although the ADP report indicated a rise of 63,000 private sector jobs in February, surpassing expectations, the subsequent nonfarm payroll report revealed an increase in the unemployment rate to 4.4%, highlighting emerging job losses due to AI and creating uncertainty about the economic outlook.
- Earnings Impact: Broadcom exceeded earnings expectations, resulting in a 3.4% stock increase, while Corning's shares fell nearly 7% following comments from Broadcom's CEO that dampened optimism about fiber-optic technology, reflecting market volatility in tech sectors.
- Investment Strategy Adjustments: Amid market fluctuations, the investment club increased its position in Cardinal Health and exited BlackRock entirely due to rising private credit concerns, demonstrating a proactive approach to navigating the current market landscape.
Three Dividend Growth Stocks Steadily Increasing Their Payouts
Market Volatility and Investment Strategy: With increasing market volatility, investors are considering a shift towards more defensive investment strategies, particularly focusing on dividend stocks that have a history of stable increases.
Broadcom's Performance: Broadcom Inc. is highlighted as a strong player in the AI and semiconductor sectors, with significant revenue growth and a consistent history of dividend increases, making it an attractive option for investors.
McKesson's Resilience: McKesson Corporation is noted for its stable dividend payments and growth potential, despite short-term challenges, supported by its diversified business model in healthcare.
Amphenol's Dividend Growth: Amphenol Corporation has demonstrated a strong track record of dividend increases, positioning itself as a reliable investment option, with expectations for continued earnings growth in the coming year.
